|
Skyepharma launches Flutiform in France for asthma
The Pharma Letter UK drug delivery specialist Skyepharma (LSE: SKP) has received regulatory approval and agreement on pricing reimbursement for asthma treatment Flutiform in France. Skyepharma's licensee Mundipharma, responsible for the development and … Skyepharma Jumps As It Launches Flutiform in France |
View full post on asthma – Google News